Document Type


Presentation Date



Neal J. Meropol is a medical oncologist, clinical investigator and health outcomes researcher who serves as vice president of research oncology at Flatiron Health. In this role, he leads efforts to leverage Flatiron’s technology platforms and nationwide provider network to gain insights from real-world data that accelerate research and improve quality of care for cancer patients. Prior to joining Flatiron, Neal was professor and chief of the division of hematology and oncology at University Hospitals Cleveland Medical Center and Case Western Reserve University, and associate director for clinical research at the Case Comprehensive Cancer Center.

Neal has a national reputation for his research contributions in gastrointestinal malignancies and health services research, including evaluation of new agents, predictors of response and outcome, development of tools to overcome barriers to clinical trial participation, and assessment of the economic impact of care. He previously served as chair of the National Cancer Institute Gastrointestinal Cancer Steering Committee, and currently serves on the NCI Clinical Trials and Translational Research Advisory Committee (CTAC). Neal also completed a four-year term as an elected member of the American Society of Clinical Oncology Board of Directors. He has authored more than 250 manuscripts, book chapters, and editorials related to cancer prevention, treatment, decision making, and health economics.

Neal received his undergraduate degree in philosophy from Princeton University and MD from Vanderbilt University. He was a resident in internal medicine at Case Western Reserve University, and completed hematology and medical oncology fellowships at the University of Pennsylvania. He spent a sabbatical at the Leonard Davis Institute of Health Economics at the Wharton School of the University of Pennsylvania.


This presentation will use cancer therapeutic development as a use case for exploring the emerging role of real-world evidence. The current availability of electronic health records with rich information about patients gathered during their routine care is rapidly changing the landscape of evidence generation in medicine. Recent advances have accelerated the introduction of new diagnostics and treatments into clinical practice.

Learning Objectives:

  1. Understand potential sources of real-world data for use in evidence generation to guide drug development and patient care.
  2. Describe the opportunities and limitations of observational research using real-world data derived from electronic health records.
  3. Review examples of real-world data use in oncology drug development.



Included in

Public Health Commons